uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The Janus faces of CD40 in cancer
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
University of Crete Medical School.
2009 (English)In: Seminars in Immunology, ISSN 1044-5323, E-ISSN 1096-3618, Vol. 21, no 5, 301-307 p.Article, review/survey (Refereed) Published
Abstract [en]

CD40 is a TNF receptor family member that is widely recognized for its prominent role in immune regulation and homeostasis. Expression of CD40 is not restricted to normal lymphoid cells but is also evident in the majority of haemopoietic and epithelial malignancies where it has been implicated in oncogenic events. Accumulating evidence, however, suggests that the CD40 pathway can be exploited for cancer therapy by virtue of its ability to stimulate the host anti-tumor immune response, normalize the tumor microenvironment and directly suppress the growth of CD40-positive tumors. Here, we provide an overview of the multifaceted functions of the CD40 pathway in cancer and its emerging role in the treatment of malignancy.

Place, publisher, year, edition, pages
2009. Vol. 21, no 5, 301-307 p.
Keyword [en]
CD40, Cancer, Pathogenesis, Therapy
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-110786DOI: 10.1016/j.smim.2009.07.001ISI: 000274725200008PubMedID: 19647448OAI: oai:DiVA.org:uu-110786DiVA: diva2:278341
Available from: 2009-11-25 Created: 2009-11-25 Last updated: 2011-01-31Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Oncology, Radiology and Clinical Immunology
In the same journal
Seminars in Immunology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 153 hits
ReferencesLink to record
Permanent link

Direct link